Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Sign in
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Clinical Topics
View All
Addiction
Anxiety
Bipolar Disorder
Depression
Difficult to Treat Depression
Emerging Approaches in Schizophrenia
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
View All
Robert Lasser, MD
JCP
Original Research
Long-Term Safety and Efficacy of Zuranolone in MDD
December 27, 2023
Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
Andrew J. Cutler
,
Gregory W. Mattingly
,
Susan G. Kornstein
, et al
JCP
Original Research
Effect of Zuranolone vs Placebo in MDD
February 20, 2023
This phase 3 RCT found significant improvement in depressive symptoms with zuranolone beginning at day 3 of treatment.
Anita H. Clayton
,
Robert Lasser
,
Indrani Nandy
, et al
JCP
Original Research
Effect of Zuranolone on Anxiety and Insomnia in Postpartum Depression
January 30, 2023
Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived functional health in patients with PPD.
Kristina M. Deligiannidis
,
Leslie Citrome
,
Ming-Yi Huang
, et al
JCP
Original Research
A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram
August 15, 2013
Madhukar H. Trivedi
,
Andrew J. Cutler
,
Cynthia Richards
, et al
